For Women With Early Breast Cancer, Herceptin Treatment Can Be Much Shorter

however she added, “I’d like to see the data, as well as see This kind of peer-reviewed, before I make a big practice change.”

from the meantime, the results should reassure women who from the past had to quit Herceptin after only six months because of side effects, Dr. Litton said.

She had a patient like that will whom she had worried about. “currently I don’t feel bad,” Dr. Litton said.

Dr. Earl’s study, called the Persephone trial, included 4,089 women in Britain who were picked at random to take the drug for six or 12 months, along with standard chemotherapy. The women were 23 to 82 years old, which has a median age of 56. They were followed for a median of more than 5 years.

After four years, the disease-free survival rate was 89.4 percent in those treated for six months, as well as 89.8 percent from the 12-month group.

Disease-free survival means they had no signs of breast cancer, as well as the lack of difference between the two groups suggests that will their overall survival should be equal as well, Dr. Johnson said, though longer follow-up would likely be needed to be sure.

Dr. Earl said they would likely be followed for 10 years.

Toxicity can build up over time, as well as with the shorter course, half as many women had to quit treatment early because of heart problems: 4 percent from the six-month group, versus 8 percent from the 12-month group.

Earlier studies that will proved Herceptin’s effectiveness treated patients for a year, a somewhat arbitrary duration, however one that will became the standard of care because there was data to support This kind of.

To change that will standard, researchers had to produce evidence that will This kind of could be safely done. Dr. Earl’s study will be the first step in that will direction.